News and Trends 23 Nov 2022 Chiesi marks start of Biotech Center of Excellence for the future of medicine in Parma An impressive crowd gathered at Chiesi Pharmaceutical Group yesterday (November 21) to mark the much-anticipated start of work at its Biotech Center of Excellence, bringing the future of medicine to Parma. Guests, which included Vice Minister of Business and Made in Italy, Valentino Valentini, joined to celebrate the start of the work on the building, […] November 23, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Italian study shows CRISPR/Cas9 deletion of Interleukin-30 reduces prostate cancer growth Metastatic prostate cancer is a leading cause of cancer death in men worldwide. Interleukin (IL)-30, a cytokine that may perform immunomodulatory functions, promotes prostate cancer onset and development, but whether it can be a suitable therapeutic target remains to be investigated. In a new study published in the Journal of Hematology & Oncology, researchers at […] October 17, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Reveal Genomics reveals more HER2DX breast cancer validation data Reveal Genomics, S.L. says it has received more validation of HER2DX, the world’s first specialized genomic test for HER2+ breast cancer. Valentina Guarneri from the University of Padova presented the data at the European Society of Medical Oncology Congress 2022 in Paris, France. The data obtained from the analysis of tumor samples from the PerELISA […] September 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Aug 2022 Santhera and ReveraGen announce first patient with Becker muscular dystrophy dosed in FDA-funded pilot study The first patient has been dosed in a phase 2 pilot study looking at a treatment for muscular dystrophy. Santhera Pharmaceuticals and ReveraGen BioPharma made the announcement that vamorolone is to be assessed in patients with Becker muscular dystrophy (BMD). The study is being funded by the U.S. Food and Drug Administration (FDA). Eric Hoffman, […] August 22, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Aug 2022 New partnership delivers clinically proven products and manufacturing processes for advanced therapies AGC Biologics has announced its partnership with supplier of human mesenchymal stem/stromal cells (hMSCs), RoosterBio Inc. The partnership, the companies say creates an end-to-end solution for the development and production of hMSCs and exosome therapeutics using RoosterBio’s well-established cell and media products and process development services together with AGC’s cell and gene therapy manufacturing capabilities. […] August 17, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 AGC Biologics announces gene therapy partnership with Altheia Science A new development partnership between gene therapy company Altheia Sciences, which pioneers cell and gene treatments, and AGC Biologics, will look at strategies to treat autoimmune disease and cancer. Specifically, the partnership will help advance development of autoimmunity treatments, focused on modulating PD-L1 expression in patients’ hematopoietic stem and progenitor cells, into clinical testing. PD-L1 […] July 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2022 Forcefield Therapeutics Launched to Treat Heart Attacks with Protein Drugs The startup Forcefield Therapeutics has been unveiled in the UK with €6M (£5.5M) backing from the investment firm Syncona. The mission is to develop the first drugs to safeguard heart muscle from damage during heart attacks. A sudden heart attack, also known as acute myocardial infarction, happens when the flow of blood to the heart […] April 25, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jan 2022 Two Gene Therapy Players Launch IPOs on Stormy Stock Market After a drought of more than a year, the European gene therapy sector saw initial public offerings from Genenta Science and Genflow Biosciences. The firms aim to shine as biotech stocks elsewhere perform poorly. Until recently, European gene therapy companies were going through a dry spell in terms of launching initial public offerings (IPO). The […] January 21, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jan 2022 Engitix Builds Liver Disease Pipeline with Series A and Drug Collaboration With the close of its Series A round at €48M ($54M), the tissue models company Engitix has shifted its business from providing drug discovery services to developing its own treatment pipeline for liver diseases. When Engitix was spun out of University College London in 2016, the startup primarily aimed to provide tissue models to pharmaceutical […] January 19, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2021 Sofinnova Taps into Italian Gene Therapy with Three Seed Financings The French investor Sofinnova Partners has injected a total of €6M into three Italian gene therapy companies, cementing Italy’s reputation as a European center for cell and gene therapies. Last month, the venture capitalist Sofinnova Partners used its Telethon fund to inject cash into AAVantgarde Bio, Borea Therapeutics, and Alia Therapeutics. The three firms will […] July 12, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2020 Record Series A for Italian Biotech Funds Autoimmune Therapy Italian biotech Enthera raised €28M in Series A funding to develop its drug candidate for type 1 diabetes and inflammatory bowel disease and take it to human trials. Enthera was founded in 2016 and is the first company to ‘graduate’ from the BiovelocITA accelerator program in Milan, which is supported by French life science investor […] July 28, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 11 May 2020 Italian Pharma Getting Back to Normal With Two Biotech Acquisitions Despite the country being hard hit with Covid-19, Italian pharma seems to be getting back to business as usual with two oncology-related biotech acquisitions in the last week. The most recent acquisition was of French immuno-oncology company ElsaLys Biotech by Mediolanum Farmaceutici, a pharmaceutical group based in Milan. The French biotech has several candidate drugs […] May 11, 2020 - 4 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email